Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
28 mars 2024 16h01 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19 mars 2024 16h05 HE
|
Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 mars 2024 16h39 HE
|
CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
13 mars 2024 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Retail Opportunity Investments Corp. Schedules First Quarter Earnings Release and Conference Call
11 mars 2024 09h00 HE
|
Retail Opportunity Investments Corp.
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Retail Opportunity Investments Corp. (NASDAQ: ROIC) will issue financial and operational results for the first quarter ended March 31, 2024, after the...
Arbutus to Participate in Two Upcoming Investor Conferences
08 mars 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 mars 2024 16h01 HE
|
MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
07 mars 2024 07h00 HE
|
Optinose, Inc.
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06 mars 2024 07h01 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
06 mars 2024 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...